Xiaofeng Tang

924 citations
57 papers · 683 indexed · h-index 16
Topics
Blood Pressure and Hypertension Studies (9 papers)Hormonal Regulation and Hypertension (7 papers)Cerebrovascular and Carotid Artery Diseases (7 papers)
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Xiaofeng Tang

53 papers receiving 675 citations

Peers

Xiaofeng Tang
Comparison fields: 5 of 99
  • Surgery 164
  • Molecular Biology 138
  • Endocrinology, Diabetes and Metabolism 134
  • Cardiology and Cardiovascular Medicine 117
  • Epidemiology 114
Replace Yongjun Wang with:
Yongjun Wang China
Xin Liao China
Maciej Kajor Poland
Shanshan Tang China
Mingjie Shao China
Ender Çoşkunpınar Türkiye
Sung Hak Park South Korea
Xianxian Zhao China
Xiaofeng Tang relative to Yongjun Wang China Yongjun Wang's profile →
Citations per field
00.5×3.4×
Yongjun Wang · 1×
Citations per year

Countries citing papers authored by Xiaofeng Tang

Since Specialization
Citations

This map shows the geographic impact of Xiaofeng Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofeng Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofeng Tang more than expected).

Fields of papers citing papers by Xiaofeng Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofeng Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofeng Tang. The network helps show where Xiaofeng Tang may publish in the future.

Co-authorship network of co-authors of Xiaofeng Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofeng Tang. A scholar is included among the top collaborators of Xiaofeng Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofeng Tang. Xiaofeng Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 6
3 1
4 0
5 1
6 0
7 0
8 1
9 6
10 52
11 37
12 21
13 1
14 13
15 12
16 14
17 5
18 13
19 12
20 10

About Xiaofeng Tang

Xiaofeng Tang is a scholar working on Hepatology, Cardiology and Cardiovascular Medicine and Aging, having authored 57 papers that have together received 683 indexed citations. Recurring topics across this work include Blood Pressure and Hypertension Studies (9 papers), Hormonal Regulation and Hypertension (7 papers) and Cerebrovascular and Carotid Artery Diseases (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (134 citations), Hepatology (60 citations) and Health Informatics (10 citations). Xiaofeng Tang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Pingjin Gao, Dingliang Zhu, Jianzhong Xu, Weiqing Han, Ji‐Guang Wang, Lian Xu, Dingliang Zhu, Yanan Du, Yan Yang and Qihong Wu. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026